Press Releases - Ipsen UK
Ipsen media library
Ipsen CEO David Loew is elected to EFPIA leadership; joins industry partners to warn of impact of EU pharma legislation - Global
Ipsen puts patients first
Press Releases - Ipsen UK
Press releases
Emirates Oncology Society And Ipsen Break Guinness World Record For Largest Awareness Ribbon | Press Release Network
Ipsen: Patients Living with Spasticity Want Long-lasting Symptom Relief | Business Wire
Press Releases - Ipsen UK
Press Releases - Ipsen UK
Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases
Ipsen's quick fix backfires | Evaluate
Ipsen Goes All In on Neuro with $1 Billion+ Deal For Exicure's Oligonucleotides | BioSpace
Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3 | Business Wire
06-01-2016-PR-Ipsen-Galderma-APAC-Dysport-Aesthetics
Ipsen Inc. | Aviation Pros
Press Releases - Ipsen UK
Ipsen NHS Study Published - IFOPA - International Fibrodysplasia Ossificans Progressiva Association
Mayoly Spindler completed the acquisition of Ipsen's CHC branch - MAYOLY SPINDLER laboratoire indépendant français
Global Biopharmaceutical Company, Ipsen Announces New Headquarters for North America will be located in Cambridge, Massachusetts | Financial Post
Ipsen CEO steers clear of gene therapy despite rare disease push
Ipsen - David Meek appointed as Chief Executive Officer of Ipsen http://www. ipsen.com/wp-content/uploads/2016/07/11-07-2016-PR-David-Meek-new-CEO-of- Ipsen.pdf | Facebook
Ipsen to acquire exclusive rights to investigational ERK inhibitor as part of its existing research collaboration with AGV Discovery | Liberi Group
Merrimack Provides Ipsen Report That Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership
